Molecular Profile |
Indication/Tumor Type |
Response Type |
Relevant Treatment Approaches |
Therapy Name |
Approval Status |
Evidence Type |
Efficacy Evidence |
References |
KIT W557_K558del
|
Advanced Solid Tumor
|
sensitive |
KIT Inhibitor
|
Regorafenib
|
Preclinical |
Actionable |
In a preclinical study, transformed cells expressing KIT W557_K558del demonstrated sensitivity to treatment with Stivarga (regorafineb) in culture, resulting in reduced cell viability (PMID: 25239608).
|
25239608
|
KIT W557_K558del
|
Advanced Solid Tumor
|
sensitive |
KIT Inhibitor
|
Sunitinib
|
Preclinical |
Actionable |
In a preclinical study, transformed cells expressing W557_K558del demonstrated sensitivity to treatment with Sutent (sunitinib) in culture, resulting in reduced cell viability (PMID: 25239608).
|
25239608
|
KIT W557_K558del
|
Advanced Solid Tumor
|
sensitive |
KIT Inhibitor
|
Dasatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Sprycel (dasatinib) inhibited growth and induced apoptosis of transformed cells expressing KIT W557_K558del in culture (PMID: 17699867).
|
17699867
|
KIT W557_K558del
|
Advanced Solid Tumor
|
sensitive |
KIT Inhibitor
|
Imatinib
|
Preclinical |
Actionable |
In a preclinical study, transformed cells expressing KIT W557_K558del demonstrated sensitivity to treatment with Gleevec (imatinib) in culture, resulting in reduced cell viability (PMID: 25239608).
|
25239608
|
KIT W557_K558del
|
Advanced Solid Tumor
|
sensitive |
KIT Inhibitor
|
Nilotinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Tasigna (nilotinib) inhibited growth of transformed cells expressing KIT W557_K558del in culture (PMID: 17699867).
|
17699867
|
KIT W557_K558del
|
Advanced Solid Tumor
|
sensitive |
KIT Inhibitor
|
Ponatinib
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, transformed cells expressing KIT W557_K558del demonstrated sensitivity to treatment with Iclusig (ponatinib) in both culture and cell line xenograft models, resulting in reduced cell viability and near complete tumor regression (PMID: 25239608).
|
25239608
|
KIT W557_K558del
|
gastrointestinal stromal tumor
|
sensitive |
|
PD-0325901
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, PD-0325901 treatment inhibited Erk phosphorylation and decreased expression of ETV1 and CXCR4 in gastrointestinal stromal tumor cells harboring KIT W557_K558del (PMID: 26936919).
|
26936919
|